NASDAQ: EPIXEssa Pharma Inc Stock
$0.24+0.00 (+0%)
Updated Sep 2, 2025
EPIX Price
$0.24
Fair Value Price
N/A
Market Cap
$11.31M
52 Week Low
$0.22
52 Week High
$7.88
P/E
-0.43x
P/B
0.1x
P/S
N/A
PEG
N/A
Dividend Yield
707.54%
Revenue
$0.00
Earnings
-$25.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$21M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EPIX Overview
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EPIX's potential to beat the market
- EPIX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EPIX
RankedUnranked of 482
RankedUnranked of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.84 | A | |
| $38.46 | A | |
| $11.68 | A |
Be the first to know about important EPIX news, forecast changes, insider trades & much more!
EPIX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EPIX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EPIX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EPIX is good value based on its book value relative to its share price (0.1x), compared to the US Biotechnology industry average (4.65x)
P/B vs Industry Valuation
EPIX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more EPIX due diligence checks available for Premium users.
Valuation
EPIX fair value
Fair Value of EPIX stock based on Discounted Cash Flow (DCF)
Price
$0.24
Fair Value
$2.33
Undervalued by
89.72%
EPIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EPIX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.43x
Industry
-112.37x
Market
34.73x
EPIX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.1x
Industry
4.65x
EPIX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EPIX's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.0M
Profit Margin
0%
EPIX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$110.5M
Liabilities
$1.6M
Debt to equity
0.02
EPIX's short-term assets ($110.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EPIX's short-term assets ($110.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EPIX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EPIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.2M
Investing
$3.8M
Financing
$0.0
EPIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EPIX vs Biotech Stocks
Essa Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.